Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|May 29, 2009
Mutation in TET2 in myeloid cancersFrançois Delhommeau, Sabrina Dupont, Véronique Della Valle, et al.
Oncogene|June 24, 2020
Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasmsMira El-Khoury, Xénia Cabagnols, Matthieu Mosca, et al.
NPJ Precision Oncology|February 26, 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patientsDamien Vasseur, Ahmadreza Arbab, Fabiola Giudici, et al.
Hemasphere|June 21, 2024
The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness programAlexandre Fagnan, Zakia Aid, Marie Baille, et al.
Blood Cancer Discovery|May 24, 2021
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignanciesAline Renneville, Jessica A Gasser, Daniel E Grinshpun, et al.
Cells|June 24, 2022
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved TestDamien Vasseur, Hela Sassi, Arnaud Bayle, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
Blood|August 18, 2021
Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasmsMatthieu Mosca, Gurvan Hermange, Amandine Tisserand, et al.
American Journal of Hematology|January 6, 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 studyJean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Pageof 6